Protemix Corp. Ltd.
This article was originally published in Start Up
Protemix Corp. Ltd. is leveraging the expertise of its founder, internationally known scientist Garth Cooper, MD, PhD, to discover and develop novel therapies for preventing and treating diabetes and other metabolic disorders and their complications, as well as cardiovascular disease.
You may also be interested in...
The other land down under is getting serious about moving its affordable world-class science to global markets. For start-ups, establishing a US presence may be key. The three NZ start-ups that we profile in this issue--CoDa Therapeutics, Proacta and Protemix--have found their own paths for taking their technologies to the worldwide market via a US presence.
Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.